Do NAD+ IV infusions reverse aging, restore energy, and repair your cells?
Claim attributed to IV and longevity/wellness clinics (e.g., Restore Hyper Wellness and many independent IV-drip clinics) , "Reverses aging, restores energy, repairs cells" is marketing language used by IV and longevity clinics that sell NAD+ infusions for roughly $200 to $1,000-plus per session. No clinic or manufacturer points to a human trial showing these specific outcomes, and the strong version of the claim is contradicted by the industry's own scientists, Restore Hyper Wellness's Chief Science Officer, Rachel Pojednic, concedes intravenous NAD+ is "very inefficient" at raising NAD+ inside the cell.
No controlled human trial has ever tested whether an NAD+ drip reverses aging, restores energy, or repairs cells, and the one thing that has been measured, the pharmacokinetics, suggests most of the infused NAD+ is broken down before it reaches the inside of a cell. The biology is real; the marketed outcome is asserted as fact, sold for hundreds of dollars a session, and contradicted by the limited evidence that exists.
It raises a blood marker for a few hours and a wave of side effects in the room, and no human study has ever shown it does a single thing the brochure promises: not aging reversed, not energy restored, not cells repaired.
What it’s supposed to target
- NAD+ repletion
- Sirtuins and PARPs
- Mitochondrial metabolism
- IV delivery (bypasses gut)
NAD+ IV drips share NMN's premise, NAD+ falls with age and powers the sirtuin and PARP repair enzymes, but add a delivery claim: infusing NAD+ straight into a vein bypasses the gut and supposedly guarantees the molecule reaches your cells, recharging mitochondrial metabolism better than any pill.
The NAD+ biology is the same plausible, unproven longevity story as NMN. The IV twist is shakier: it is unclear how much intact NAD+ actually enters cells versus being broken down to precursors first, infusions must run slowly to avoid real discomfort, and there is no outcome evidence the drip does anything a cheaper oral precursor would not. A real coenzyme, an expensive delivery claim, no proof of the payoff.
Mechanism is theory, not proof. A plausible pathway explains why something might work, not whether it does. The verdict rests on the evidence below, not the elegance of the theory.
What would have to be true
Infused NAD+ would have to survive in the bloodstream and cross into cells intact. This link does NOT hold cleanly: NAD+ is a large, charged molecule, and the human pharmacokinetic data show it is rapidly cleaved into nicotinamide, ADP-ribose and related metabolites before plasma levels even rise.
Higher blood NAD+ would have to translate into durably higher NAD+ inside tissues. This link is UNSHOWN: no human study has demonstrated that an IV raises intracellular/tissue NAD+ in a lasting way; reviews flag tissue specificity and bioavailability as open questions.
Durably higher tissue NAD+ would have to produce the named clinical outcomes, reversed aging, more energy, cellular repair, in healthy people. This link is UNTESTED: there is no controlled human trial of IV NAD+ on any of these endpoints.
The benefit would have to be specific to intravenous NAD+, not borrowed from oral precursors or animal data. This link FAILS in the marketing: the more developed (and still modest, mixed) human evidence is for oral NR/NMN, a different question from the IV NAD+ claim assessed here.
What the evidence actually shows
No human trial has tested the headline claim
The marketed promise is an outcome claim: that a drip will reverse aging, restore energy, and repair cells. The first thing to say plainly is that no randomized or controlled human trial has ever measured any of those outcomes after intravenous NAD+. A 2026 PRISMA-guided systematic review of NAD+ for anti-aging and wellness searched the literature and reported that no eligible outcomes trials evaluated intravenous or intramuscular NAD+ itself for these indications; the human clinical evidence it could find was 'primarily oral NR and NMN,' limited in number, size and duration, and the overall picture for anti-aging efficacy 'remains inconclusive.'
The single randomized, double-blind, placebo-controlled trial that included an NAD+ IV arm (a ChromaDex/Niagen pilot, posted as a preprint in 2024) was an acute blood-level and safety study only. It compared an NR-based IV, an NAD+ IV, oral NR and saline in generally healthy adults, and measured how much blood NAD+ rose over a few hours. It did not measure aging, energy, fatigue, or cellular repair. Tellingly, the NAD+ IV produced a smaller and slower rise in blood NAD+ than the sponsor's own NR-based infusion. The study remains an unrefereed preprint funded by the maker of the competing product.
The pharmacology cuts against the mechanism
The marketing leap is that pushing NAD+ into a vein raises NAD+ inside your cells. The one human study designed to watch what actually happens to infused NAD+ suggests otherwise. In a 2019 pilot, eleven men (eight on NAD+, three on saline) received 750 mg of NAD+ intravenously over six hours. Plasma NAD+ did not rise at all for the first two hours, the infused NAD+ was, in the authors' words, 'rapidly and completely removed from the plasma for at least the first 2 h.' Only later did NAD+ climb, by roughly 398% at hour six. But it did not climb alone: the breakdown products rose in parallel, nicotinamide by ~409%, ADP-ribose by ~393%, methyl-nicotinamide by ~350%. That is the chemical signature of NAD+ being cleaved apart and salvaged, not delivered intact to cells.
The most striking confirmation comes from inside the industry. Restore Hyper Wellness's Chief Science Officer, Rachel Pojednic, a Stanford-affiliated researcher whose own company sells these infusions, told NPR that NAD+ has 'no easy door' to enter the cell from the bloodstream, and elsewhere that IV NAD+ is 'very inefficient' at raising NAD+ in the cell. When a seller's own scientist says the delivery mechanism barely works, that admission carries unusual weight precisely because it cuts against her commercial interest.
What people actually feel: side effects, not a measured 'recharge'
A 2026 retrospective review of patient records at a Restore clinic in Austin looked at a small group given 500 mg/day of IV NAD+ for four days. All six NAD+ patients reported moderate-to-severe abdominal cramping, diarrhea, nausea, vomiting, raised heart rate, throat pain and chest pressure. To make the infusions tolerable, they had to be slowed, averaging about 97 minutes, versus roughly 37 minutes for the NR comparator. This is the 'rushing' or 'flushing' sensation that clinics themselves warn about; it is a dose-rate effect, not a sign that anything therapeutic is happening.
The same study is instructive for what it did not find. The clinic collected validated fatigue, cognition, quality-of-life, sleep and pain questionnaires at baseline and 30 days, but it did not analyze or report those as efficacy outcomes, there was no placebo arm, and the authors state the design 'does not imply causal inference.' So even the clinic's own data do not deliver the energy or anti-aging 'win' the marketing implies.
Independent reviewers reach the same conclusion
Where the funding is not commercial, the verdict is consistent. An independent review funded by the Slovenian Research Agency stresses 'many unknowns regarding pharmacokinetics and pharmacodynamics, particularly bioavailability, metabolism, and tissue specificity of NAD+ boosters,' notes there are few human studies on vitality or lifespan, that the knowledge base is largely from cell culture and model organisms, and that there are 'no long-term human safety trials.' A clinical-evidence review in Pharmaceuticals similarly finds that the older human IV NAD/NADH data exist only in disease settings (open-label Parkinson's work, null schizophrenia trials), and that infused NAD/NADH is likely cleaved to nicotinamide and ADP-ribose rather than taken up intact.
Mainstream reporting lands in the same place. The University of Delaware's Christopher Martens told NPR, 'I think now the cart may be well ahead of the horse,' and added that 'there's an influencer culture that's really promoting the use of NAD+ that is now interfering with our ability to do rigorous science.' The article's plain bottom line: the NAD+ products on the market 'aren't proven to do the average person much good,' while IV sessions 'can run anywhere from $200 to upwards of $1,000 for one drip session.'
Studies, graded, and who paid
Well supported as cell biology: NAD+ is a central coenzyme for mitochondrial ATP production and for sirtuins/PARPs; the age-related decline is best characterized in animals and cell culture, less so in humans.
Actively undercut. The one human pharmacokinetic study shows plasma NAD+ does not rise for the first 2 hours while breakdown products climb in parallel, a degradation signature. The seller's own Chief Science Officer calls IV NAD+ 'very inefficient' with 'no easy door' into the cell.
Untested. No randomized or controlled human trial has measured an aging endpoint after IV NAD+. A 2026 PRISMA systematic review found no eligible outcomes trials of intravenous or intramuscular NAD+ for anti-aging or wellness.
Untested for the IV route. The fatigue/energy signals in this field come from oral precursors (NR/NMN/NADH), often in disease populations, not from intravenous NAD+. The only clinic study that even collected fatigue surveys did not analyze or report them as efficacy.
| # | Study | Type | Size | Funding / COI | Key limitations |
|---|---|---|---|---|---|
| 4 | 2026 PRISMA systematic review, NAD+ for anti-aging/wellness (Gallagher & Emmanuel, Ageing Res Rev) | PRISMA systematic review | 113 studies screened (33 human, 80 rodent); no eligible IV/IM outcomes trials found | Funding unknown Funding not displayed; lead author's disclosed commercial tie is to an aesthetics clinic that does NOT sell NAD+ products, so the review leans independent of NAD+ sellers. Treat funding as unverified. | Synthesis, not a primary trial; full text could not be fetched first-party (verified via abstract and PubMed PMID 41655607). Conclusion of 'limited/no controlled IV outcomes evidence' is load-bearing and corroborated by the seller-side RCT. |
| 2 | Only IV NAD+ RCT, ChromaDex/Niagen acute pilot (2024 preprint) | Randomized, double-blind, placebo-controlled pilot, acute blood-NAD+ and safety only | Up to ~53 healthy adults across two phases (37 in phase 1 + 16 in phase 2) | Industry-funded Conducted by ChromaDex (now Niagen Bioscience) on its own competing NR-based IV; several authors are ChromaDex employees; sponsored via Franklin Health Research. | Unrefereed preprint; measured only acute blood NAD+ and safety, no aging, energy, fatigue, or repair endpoint. NAD+ IV raised blood NAD+ LESS than the sponsor's NR IV. |
| 3 | 2019 human pharmacokinetic pilot, 6-hour NAD+ infusion (Grant et al.) | Pharmacokinetic pilot (controlled, non-randomized) | n=11 (8 NAD+, 3 saline), men aged 30–55 | Industry-funded Funded by NAD+ Research Inc.; co-author/director R. Mestayer is medical director of the Springfield Wellness Center, which sells IV NAD+ as a clinical therapy (disclosed COI). | Tiny, short, acute; no efficacy/aging/energy endpoint. Plasma NAD+ flat for first 2h then +398%, with breakdown metabolites rising in parallel, degradation signature. No adverse events in this slow 6h protocol. |
| 1 | 2026 Restore clinic retrospective, IV NAD+ vs NR tolerability (Reyna et al., Front Aging) | Retrospective observational pilot (real-world EMR) | n=14 (NAD+ n=6, NR n=8); 500 mg/day x4 days | Industry-funded Funded by Restore Hyper Wellness; NR product donated by Niagen Biosciences; multiple authors employed by Restore (bias acknowledged in the paper). | No placebo; not designed to show efficacy. All 6 NAD+ patients had moderate-to-severe GI/cardiac side effects; mean NAD+ infusion ~97 min vs ~37 min for NR. Fatigue/QoL surveys were collected but not analyzed or reported as efficacy. |
| 6 | Independent uncertainties review, NAD+ boosting strategies (Poljsak et al., Antioxidants 2022) | Narrative review (independent) | na (evidence synthesis) | Independent Funded by the Slovenian Research Agency (P3-0388, P3-0019); authors declare no conflict of interest, the genuine non-commercial counterweight. | Narrative, not systematic; but the central point holds, bioavailability, metabolism and tissue specificity of NAD+ boosters are unresolved, and there are no long-term human safety trials. |
| 5 | Clinical-evidence review, targeting NAD therapeutically (Radenkovic, Reason, Verdin, Pharmaceuticals 2020) | Narrative clinical-evidence review | na | Mixed No external funding reported; authors disclose commercial interests in NAD-related ventures (longevity institute, Repair Biotechnologies, Napa Therapeutics/Seneque). | Narrative review; relevant point is that historical human IV NAD/NADH data are sparse and confined to disease populations, and infused NAD/NADH is likely cleaved before cellular uptake. |
| 7 | NPR/KPBS reporting with named experts (Aubrey, 2026) | Journalism with expert interviews | na | Independent Public-radio reporting; the key disconfirming quote ('no easy door,' 'very inefficient') is from Restore's own CSO and cuts against her commercial interest. | Journalism, not a study; used for verbatim expert statements and documented pricing ($200–$1,000+/session), not as primary efficacy evidence. |
| 8 | ChromaDex/Niagen commercial disclosures (BioSpace, 2024) | Company press release / financial disclosure (money trail only) | na | Industry-funded Primary commercial source (the seller); used only to establish the verifiable money trail, never as evidence of efficacy. | Marketing/financial material. Some figures (1,200+ clinics, 200+ Restore locations, ~$129.4M 2025 net sales) come from later ChromaDex releases, not this June-2024 page, see human-checks. |
The funding pattern is the story, but it runs the opposite way from the usual hype case. Here the studies that exist do not even claim the marketed benefit: they measure surrogate endpoints (blood NAD+ levels, acute safety, tolerability) and are funded by parties that sell NAD+ or NAD+-precursor infusions, ChromaDex/Niagen (the only RCT, on its own product), NAD+ Research Inc. (the PK pilot; its director runs an IV clinic), and Restore Hyper Wellness (the tolerability retrospective; authors are employees).
The most credible facts against the claim come from inside the industry. The seller's own Chief Science Officer says IV NAD+ is inefficient with 'no easy door' into the cell; the sponsor's own RCT shows its NAD+ IV underperforms its NR IV; the seller's own retrospective documents a 100% side-effect rate. Statements and results that cut against a funder's commercial interest are unusually trustworthy.
Every genuinely independent source, the PRISMA systematic review and the Slovenian-government-funded uncertainties review, lands on 'unproven' and 'unresolved pharmacokinetics.' No independent study supports the marketed outcomes.
The designs are uniformly short and surrogate. The longest human exposure on record is a six-hour infusion; the rest are single-day or four-day protocols measuring blood chemistry or side effects. Nothing in the human record is built to detect aging or durable energy change.
Unproven ≠ disproven
Unproven is not disproven, and the distinction matters here. The specific outcomes, reversed aging, restored energy, cellular repair, have essentially never been tested in healthy humans in a controlled way, so we cannot say an NAD+ drip has been shown to fail at them. What we can say is that the mechanism it relies on has been partly contradicted (the infused molecule is largely broken down before reaching cells), and that the benefit is being asserted as established fact and sold for hundreds of dollars a session. That combination, an affirmative, monetized efficacy claim with no outcomes data and disconfirming pharmacology, is why this lands at Unsupported rather than a neutral Unproven. It stops short of Disproven: a clinical benefit by some untested route is not logically excluded.
There are honest structural reasons the good evidence is missing. NAD+ itself is an old, unpatentable molecule, so no manufacturer has a strong incentive to fund the large, long-term, placebo-controlled aging and energy trials that would be needed to prove the marketed claims, meanwhile clinics already sell it profitably as a cash-pay wellness service with no trial data required. Where industry has invested (ChromaDex), it has steered research toward its proprietary, patent-protected nicotinamide riboside and toward short surrogate endpoints rather than clinical outcomes. And as one academic put it, influencer culture has begun 'interfering' with the ability to run rigorous studies. The absence of proof is real uncertainty, not a verdict of harmlessness or of no effect.
Where claim and evidence diverge
The claim is about outcomes (aging reversed, energy restored, cells repaired). The evidence is about surrogates (does blood NAD+ go up; is a 4-day course tolerable). No human study bridges that gap for the intravenous route.
The claim assumes delivery into cells. The pharmacology shows degradation in the blood, NAD+ flat for two hours while its breakdown products climb, and the seller's own scientist concedes there is 'no easy door' into the cell.
The claim implies a benefit specific to IV NAD+. The few suggestive fatigue/energy signals in this field belong to oral precursors (NR, NMN, NADH), frequently in disease populations, exactly the data marketers borrow and the IV claim cannot lean on.
The claim is sold as a 'recharge.' What the clinic's own records actually document is a 100% rate of moderate-to-severe side effects, requiring the drip to be slowed, and fatigue questionnaires that were collected but never reported.
The money trail
Direct-to-consumer pricing: NPR reports NAD+ IV sessions run from $200 to upwards of $1,000 for a single drip; multi-day 'loading' protocols and monthly maintenance push first-year costs into the thousands. NAD+ IV is billed as elective wellness and is almost never covered by insurance.
ChromaDex / Niagen Bioscience built a commercial NAD+ business around a patent-protected precursor. It markets a pharmaceutical-grade IV/injectable nicotinamide riboside ('Niagen IV/Niagen+') as faster and better tolerated than NAD+ IV. Its launch materials estimated the North American NAD+ IV market at over $100M (2023) within a roughly $1.15B North American IV-hydration market.
The only IV NAD+ randomized trial was funded and conducted by ChromaDex on its own competing NR-based product, a conflict that favors its proprietary infusion over generic NAD+ IV.
The 2019 pharmacokinetic pilot was funded by NAD+ Research Inc., whose director, Richard Mestayer, is also medical director of the Springfield Wellness Center, which sells clinical IV NAD+ infusions.
The 2026 tolerability retrospective was funded by Restore Hyper Wellness, a national IV-clinic chain, with the NR comparator donated by Niagen Biosciences; multiple authors are Restore employees, and the company's CSO publicly promotes the precursor IV products her company sells.
The honest read
Strip away the brochure language and this is a marketed, monetized claim with almost nothing behind it. There is no controlled human trial showing that an NAD+ drip reverses aging, restores energy, or repairs cells; the only randomized study with an NAD+ arm measured blood chemistry for a few hours, and the only human pharmacokinetic study suggests most of the infused NAD+ is cleaved apart before it reaches the inside of a cell. The most candid voices in the room are the sellers' own scientists, who concede the delivery barely works and that side effects are common.
None of this means NAD+ is unimportant, it is a genuine, central molecule in cell metabolism, and the age-related decline seen in animals is a reasonable thing to study. But 'this molecule matters' is not the same as 'paying $200 to $1,000 to drip it into your arm will make you younger.' For now the honest read is that the IV version is unproven where it has been studied and contradicted where the mechanism has been measured. If you want to engage with the NAD+ idea, the better-developed (and still modest, mixed) human evidence is for oral precursors, a different product and a different question from the one the clinics are selling.
What would change this verdict
An adequately powered, randomized, placebo-controlled trial in healthy adults showing that IV NAD+ improves a real outcome, validated fatigue/energy measures, functional capacity, or a credible aging biomarker panel, sustained beyond the acute infusion, ideally with independent (non-seller) funding.
Human evidence that an NAD+ infusion durably raises NAD+ inside tissues (not just transiently in blood), demonstrating that the molecule is delivered intact rather than broken down and salvaged.
Independent replication, by investigators with no financial stake in selling NAD+ or its precursors, confirming any such benefit, which would move this from Unsupported toward Mixed or Supported depending on effect size and durability.
Sources
- Reyna K, Heinzen G, Patel N, Ritter M, Siojo A, Legere H, Pojednic R. Intravenous infusion of NAD+ versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting. Front Aging. 2026;7:1652582.
- ChromaDex, Inc. Randomized, placebo-controlled, pilot clinical study evaluating acute Niagen+ IV and NAD+ IV in healthy adults. medRxiv preprint, posted 2024 Jun 10. doi:10.1101/2024.06.06.24308565. (Unrefereed preprint; direct URL blocked anti-bot at audit, confirm against any peer-reviewed publication.)
- Grant R, Berg J, Mestayer R, Braidy N, Bennett J, Broom S, Watson J. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Front Aging Neurosci. 2019;11:257.
- Gallagher C, Emmanuel OO. NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Res Rev. 2026 Apr;116:103057. PMID: 41655607. (ScienceDirect URL blocked anti-bot at audit; PubMed mirror below.)
- Radenkovic D, Reason, Verdin E. Clinical Evidence for Targeting NAD Therapeutically. Pharmaceuticals (Basel). 2020;13(9):247.
- Poljsak B, Kovac V, Milisav I. Current Uncertainties and Future Challenges Regarding NAD+ Boosting Strategies. Antioxidants (Basel). 2022;11(9):1637.
- Aubrey A. Marketers say NAD+ pills and infusions can boost longevity. What's the evidence? NPR / KPBS, 2026 May 11.
- ChromaDex to Launch Niagen+, First-of-Its-Kind Pharmaceutical-Grade IV/Injectable Niagen (NRC). BioSpace, 2024 Jun 13. (Commercial source; used for money trail only.)
People also ask
- Do NAD+ IV infusions actually reverse aging?
- No controlled human trial shows it. A 2026 PRISMA systematic review found no eligible outcome trials of intravenous NAD+ for anti-aging or wellness. The claim is untested for the IV route, while sessions are sold for hundreds of dollars each.
- Does an NAD+ drip actually get NAD+ into your cells?
- The evidence undercuts this. The one human pharmacokinetic study showed plasma NAD+ did not rise for the first two hours while breakdown products climbed, a degradation signature. The seller's own Chief Science Officer calls IV NAD+ very inefficient with no easy door into the cell.
- How much does an NAD+ IV drip cost?
- NPR reports single sessions run from $200 to upwards of $1,000. Multi-day loading protocols and monthly maintenance push first-year costs into the thousands. It is billed as elective wellness and almost never covered by insurance.
- Are NAD+ IV drips safe or do they have side effects?
- One clinic's own records documented a 100% rate of moderate-to-severe side effects, requiring the drip to be slowed. Fatigue questionnaires were collected but never reported as efficacy, so the energy benefit was never actually demonstrated.
Caveat is journalism, not medical advice. We check public claims against published evidence; we don’t diagnose, treat, or tell you what to take.